'We play to win': AstraZeneca details first results for oral GLP-1 and broader obesity ambitions

SAN ANTONIO — Well behind Novo Nordisk and Eli Lilly in the obesity race, AstraZeneca came to this year's ObesityWeek with three assets in hand as it hopes to "move beyond short-term weight loss" and ...